Navigation Links
Oncothyreon highlights corporate and clinical objectives for 2008
Date:1/28/2008

in our pipeline."

Oncothyreon provides the following update of its product development pipeline for 2008:

Stimuvax

The Phase 3 pivotal trial of Stimuvax in patients with non-small cell lung cancer (NSCLC), START (Stimulating Targeted Antigenic Responses To NSCLC), continues enrollment in 2008. This year Oncothyreon expects to manufacture and to continue to provide to Merck KGaA substantial quantities of both Stimuvax and placebo to support START and potentially other additional trials of Stimuvax. In addition, Oncothyreon will continue the development of a large-scale process in preparation for the manufacture of commercial quantities of Stimuvax. Oncothyreon expects to receive an additional milestone payment related to Stimuvax during 2008.

START is a multi-center, randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The study is expected to involve more than 1,300 patients in approximately 30 countries.

PX-478

Enrollment is ongoing in the Phase 1 dose escalation trial of PX-478 in patients with advanced metastatic cancer. Initial pharmacodynamic data from the early patients in this trial has been submitted for potential presentation at a scientific meeting at mid-year. More complete clinical data from this trial is expected in the second half of 2008.

PX-478 is a small molecule inhibitor of hypoxia inducible factor-1a (HIF-1a), a component of a transcription factor that is an important regulator of the tumor response to hypoxia. Pre-clinical data have demonstrated that PX-478 can induce apoptosis, or programmed cell death, in experimental tumor models, as well as the down-regulation of factors that control angiogenesis, such as vascular endothelial growth factor (VEGF). PX-478 is effective when delivered orally in animal models and
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Highlights of Economic and Business Growth in the Tampa Bay Region
3. Highlights of Economic and Business Growth in the Tampa Bay Region
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
6. Highlights of Economic and Business Growth in the Tampa Bay Region
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
9. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
10. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
11. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, a ... editorials addressing developments and pathways related to oncological ... article exploring the role of follicle-stimulating hormone (FSH) ... prostate cancer. , The article references seminal ... there could be a connection to prostate cancer ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... China, May 11 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced that it will conduct a,conference call at 10:00 ... to discuss its first quarter of fiscal year 2009 ...
... DIEGO, May 11, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... quarter ended March 31, 2009. Arena reported a net loss ... of $50.6 million, or $0.68 per share, compared to a ... of 2008 of $55.0 million, or $0.75 per share. "Receiving ...
... Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the ... received approval from the Chinese State Food and ... formulation of Perindopril, an anti-hypertension drug.Perindopril, used alone ... high blood pressure, is the latest generation of ...
Cached Biology Technology:China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2009 Financial Results 8Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril 2
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... Bonn Institute for Forensic Medicine has recorded that the ... sexual offences within their catchment area increased 10-fold between ... Deutsches rzteblatt International, Burkhard Madea and Frank Musshoff ... for the most frequent substances ( Dtsch Arztebl Int ...
... should be built in Lund, Sweden, it has been announced ... last night (28 May), seven countries voted in support of ... a further two voting with the majority. The European ... for materials research, enabling scientists to study the atomic and ...
... of a USC-led research team say they,ve made a big ... and other biological materials one that may be a ... of a piece of synthetic antibody attached to a nanowire ... If the protein the antibody binds to is present in ...
Cached Biology News:Sweden to host 1.3 billion Euro research center 2A quicker, cheaper SARS virus detector -- one easily customizable for other targets 2
... RNAi Kit is optimized for ... amounts of ready-to-use dsRNA for ... The MEGAscript RNAi Kit is ... transcription technol-ogy and includes reagents ...
... actuators as building blocks, Parker can ... ,robotic solutions that are ideal for ... base ,system, Parker can also integrate ... structures, and ,guarding., Standard or ...
... is the smallest electronic pressure controller ... mm. Parker configured this unit specifically for ... markets. Used in carrier gas flow control, ... dispensing, and hydro-dynamic focusing, the OEM-EPC offers ...
...
Biology Products: